Cover ImageSALE
市場調查報告書

血友病治療藥的全球市場 (2016∼2020年)

Global Hemophilia Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 379048
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
血友病治療藥的全球市場 (2016∼2020年) Global Hemophilia Drugs Market 2016-2020
出版日期: 2016年10月19日 內容資訊: 英文 84 Pages
簡介

血友病是X連鎖性遺傳疾病的一種,外傷出血不止,最壞的情況下會致死。全球整體約有40萬人發病,而且男性罹患率變高。有A、B型2種血友病,不過,A型血友病患者數壓倒性的高。現在從血漿取得凝血因子,及開發基因改造型的凝血因子,投藥給病人。全球血友病治療藥市場2016∼2020年關於,4.76%的年複合成長率 (CAGR) 預計成長。

本報告提供全球血友病治療藥的市場相關分析,產品概要和市場基本結構,市場規模趨勢 (今後5年的預測值),各用途、各地區的詳細趨勢,推動、阻礙市場要素與其影響力,主要企業簡介,今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 開發中產品的組合

第6章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第7章 血友病治療藥的全球市場:疾病的各種類的市場區隔

  • A型血友病治療藥的市場
  • 血友病抑制劑治療藥的市場
  • B型血友病治療藥的市場
  • 血管性血友病治療藥的市場

第8章 血友病治療藥的全球市場:治療藥的各種類的市場區隔

  • 基因改造型治療藥的市場
  • 血漿來源治療藥的市場

第9章 血友病治療藥的全球市場:疾病管理的各種類的市場區隔

  • 預防治療
  • 隨選治療
  • 抑制劑治療

第10章 血友病治療藥的全球市場:地區區分

  • 南北美洲市場
  • 歐洲、中東、非洲各國 (EMEA) 市場
  • 亞太地區市場

第11章 血友病治療藥的全球市場:推動市場要素

  • 預防治療的興趣
  • 有持續效果的藥物
  • 診斷次序的改善

第12章 推動因素的影響力

第13章 血友病治療藥的全球市場:課題

  • 診斷率低
  • 進入障礙高
  • 高額且複雜的治療方法

第14章 推動因素、課題的影響力

第15章 血友病治療藥的全球市場:趨勢

  • 技術創新的活躍
  • 基因治療產品的開發
  • 大客戶致力提高普及率的必要性

第16章 供應商環境

  • 競爭方案
  • 其他卓越供應商

第17章 主要供應商分析

  • Baxalta
  • Bayer
  • CSL Behring
  • Novo Nordisk
  • Pfizer

第18章 附錄

  • 簡稱集

第19章 關於Technavio

目錄
Product Code: IRTNTR10470

About Hemophilia

Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.

Technavio's analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Baxalta
  • Bayer
  • CSL Behring
  • Novo Nordisk
  • Pfizer

Other Prominent Vendors

  • Alnylam Pharmaceuticals
  • Amarna Therapeutics
  • Asklepios BioPharmaceutical
  • Biogen
  • BioMarin
  • Catalyst Bioscience
  • Chiesi Farmaceutici
  • Dimension Therapeutics
  • Emergent BioSolutions
  • F. Hoffmann-La Roche
  • Grifols, Kedrion Biopharma
  • Octapharma
  • rEVO Biologics
  • OPKO Biologics
  • Sangamo Biosciences
  • Spark Therapeutics
  • Swedish Orphan Biovitrum
  • UniQure Biopharma.

Market driver

  • Focus on prophylactic treatment
  • For a full, detailed list, view our report

Market challenge

  • Low diagnosis rate
  • For a full, detailed list, view our report

Market trend

  • Increase in technological innovations
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by type of disease

  • Global hemophilia A drugs market
  • Global hemophilia inhibitors treatment market
  • Global hemophilia B drugs market
  • Global von Willebrand disease treatment market

PART 08: Market segmentation by type of therapy

  • Recombinant therapies
  • Plasma-derived therapies

PART 09: Market segmentation by type of disease management

  • Prophylaxis
  • On-demand therapy
  • Inhibitor therapy

PART 10: Geographical segmentation

  • Hemophilia drugs market in Americas
  • Hemophilia drugs market in EMEA
  • Hemophilia drugs market in APAC

PART 11: Market drivers

  • Focus on prophylactic treatment
  • Drugs with prolonged action
  • Improved diagnostic procedures

PART 12: Impact of drivers

PART 13: Market challenges

  • Low diagnosis rate
  • High entry barriers
  • Cost-intensive complex treatment

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Increase in technological innovations
  • Development of gene therapy products
  • Centralized buyers should pave the way to increased penetration

PART 16: Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 17: Key vendor analysis

  • Baxalta
  • Bayer
  • CSL Behring
  • Novo Nordisk
  • Pfizer

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Process of gene therapy
  • Exhibit 03: Key buying criteria for global hemophilia drugs market 2015
  • Exhibit 04: Key customer segments of hemophilia drugs market
  • Exhibit 05: Pipeline portfolio: Global hemophilia drugs market
  • Exhibit 06: Pipeline share of major companies
  • Exhibit 07: Global hemophilia drugs market snapshot: Developed and emerging markets 2015
  • Exhibit 08: Global hemophilia drugs market 2015-2020 ($ billions)
  • Exhibit 09: Impact of factors affecting the market 2015 and 2020
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Segmentation of global hemophilia drugs market by disease type based on revenue 2015
  • Exhibit 12: Global hemophilia drugs market segmentation growth lifecycle analysis
  • Exhibit 13: Global hemophilia drugs market by disease type 2015-2020
  • Exhibit 14: Global hemophilia A drugs market 2015-2020 ($ billions)
  • Exhibit 15: Global hemophilia inhibitors treatment market 2015-2020 ($ billions)
  • Exhibit 16: Global hemophilia B drugs market 2015-2020 ($ billions)
  • Exhibit 17: Global von Willebrand disease treatment market 2015-2020 ($ millions)
  • Exhibit 18: Segmentation of global hemophilia drugs market by type of therapy based on revenue 2015
  • Exhibit 19: Global hemophilia drugs market by type of therapy 2015-2020
  • Exhibit 20: Recombinant therapies in global hemophilia drugs market 2015-2020 ($ billions)
  • Exhibit 21: Plasma-derived therapies in global hemophilia drugs market 2015-2020 ($ billions)
  • Exhibit 22: Segmentation of hemophilia inhibitors treatment market by type of disease management based on revenue 2015
  • Exhibit 23: Global hemophilia drugs market by geography 2015-2020
  • Exhibit 24: Percentage share of global hemophilia drugs market by geography 2015 and 2020
  • Exhibit 25: Global hemophilia drugs market segmentation by geography 2015-2020 ($ billions)
  • Exhibit 26: Global share of hemophilia drugs market by geography 2015
  • Exhibit 27: Global hemophilia drugs market segmentation by region: Market growth lifecycle analysis 2015
  • Exhibit 28: Global hemophilia drugs market: Country analysis based on revenue and growth rate
  • Exhibit 29: Opportunity analysis of hemophilia drugs market in Americas
  • Exhibit 30: Hemophilia drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 31: Opportunity analysis of hemophilia drugs market in EMEA
  • Exhibit 32: Hemophilia drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 33: Opportunity analysis of hemophilia drugs market in APAC
  • Exhibit 34: Hemophilia drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 35: Impact of drivers
  • Exhibit 36: Percentage share of diagnosed and undiagnosed hemophilia population 2012-2016
  • Exhibit 37: Impact of drivers and challenges
  • Exhibit 38: Gene therapies under development for hemophilia
  • Exhibit 39: Market share of vendors 2015
  • Exhibit 40: Geographical presence of key vendors
  • Exhibit 41: Competitive scenario of global hemophilia drugs market vendors 2015-2020
  • Exhibit 42: Baxalta: Strength assessment
  • Exhibit 43: Baxalta: Strategy assessment
  • Exhibit 44: Baxalta: Opportunity assessment
  • Exhibit 45: Baxalta: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
  • Exhibit 46: Bayer: Strength assessment
  • Exhibit 47: Bayer: Strategy assessment
  • Exhibit 48: Bayer: Opportunity assessment
  • Exhibit 49: Bayer: YoY revenue and growth rate of Kogenate FS 2013-2015 ($ billions)
  • Exhibit 50: CSL Behring: Strength assessment
  • Exhibit 51: CSL Behring strategy assessment
  • Exhibit 52: CSL Behring opportunity assessment
  • Exhibit 53: CSL Behring: YoY revenue and growth rate of hemophilia drugs 2013-2015 ($ billions)
  • Exhibit 54: Novo Nordisk: Strength assessment
  • Exhibit 55: Novo Nordisk: Strategy assessment
  • Exhibit 56: Novo Nordisk: Opportunity assessment
  • Exhibit 57: Novo Nordisk: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
  • Exhibit 58: Pfizer: Strength assessment
  • Exhibit 59: Pfizer: Strategy assessment
  • Exhibit 60: Pfizer: Opportunity assessment
  • Exhibit 61: Pfizer: Revenue of ReFacto AF/XYNTHA and BeneFIX 2015 ($ millions)
Back to Top